Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

- Describes the first evidence of clinical benefit for PROTAC protein degraders, a novel therapeutic modality -

- Data to be presented during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -

NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated safety and initial efficacy data contained in an abstract scheduled as an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29–31, 2020. The presentation will share updated data from the dose escalation portion of Arvinas’ Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer. The abstract describes two patients with ongoing confirmed prostate-specific antigen (PSA) responses, including one with an unconfirmed partial tumor response.

“We are thrilled to present the first evidence that our PROTAC protein degrader, ARV-110, can provide clinical efficacy,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “This is a significant milestone for our technology platform and for the field of targeted protein degradation.”

“While still early, we are pleased to see a safety profile to date for ARV-110 that continues to support dose escalation,” added Ron Peck, M.D., Chief Medical Officer at Arvinas. “Our trial of ARV-110 has enrolled a particularly heavily pre-treated population of patients who have exhausted most available treatment options. Most patients received both enzalutamide and abiraterone as well as prior chemotherapy. Despite this, ARV-110 demonstrated the first evidence of antitumor activity in this difficult-to-treat patient population.”

The presentation will include data collected since the abstract submission date. Dose escalation continues, with enrollment initiated above the previously disclosed daily dose of 280 milligrams.

Abstract details are as follows:
Presentation Title: First-in-human phase I study of ARV-110, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone
Abstract Number: 3500
Session Type: Oral Abstract Session
Session Track: Development Therapeutics – Molecularly Targeted Agents and Tumor Biology

For a copy of the abstract, please visit ASCO’s official website.